ResearcherAmity UniversityActive in the last 2 years
Anuradha Kirtonia
Matched on ORCID iD 0000-0002-6384-5989; OpenAlex author ID A5035100438. Sources: OpenAlex.
Their work
- Papers
- 3 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 4
2020: 1 paper · 2021: none · 2022: 1 paper · 2023: none · 2024: none · 2025: 1 paper
Papers 3
- Anticancer and therapeutic efficacy of XPO1 inhibition in pancreatic ductal adenocarcinoma through DNA damage and modulation of miR-193b/KRAS/LAMC2/ERK/AKT sig… Co-author DOI 10.1016/j.lfs.2024.123364↗
- Overexpression of laminin-5 gamma-2 promotes tumorigenesis of pancreatic ductal adenocarcinoma through EGFR/ERK1/2/AKT/mTOR cascade. Co-author DOI 10.1007/s00018-022-04392-1↗
- The implication of long non-coding RNAs in the diagnosis, pathogenesis and drug resistance of pancreatic ductal adenocarcinoma and their possible therapeutic p… First author DOI 10.1016/j.bbcan.2020.188423↗
Closest collaborators
The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Manoj Garg · 3 shared papers, 2020–2025 · strength 0.56
- Paper Anticancer and therapeutic efficacy of XPO1 inhibition in pancreatic ductal adenocarcinoma through DNA damage and modul… DOI 10.1016/j.lfs.2024.123364↗
- Paper Overexpression of laminin-5 gamma-2 promotes tumorigenesis of pancreatic ductal adenocarcinoma through EGFR/ERK1/2/AKT/… DOI 10.1007/s00018-022-04392-1↗
- Paper The implication of long non-coding RNAs in the diagnosis, pathogenesis and drug resistance of pancreatic ductal adenoca… DOI 10.1016/j.bbcan.2020.188423↗
- Gouri Pandya · 2 shared papers, 2020–2025 · strength 0.40
- Paper Anticancer and therapeutic efficacy of XPO1 inhibition in pancreatic ductal adenocarcinoma through DNA damage and modul… DOI 10.1016/j.lfs.2024.123364↗
- Paper The implication of long non-coding RNAs in the diagnosis, pathogenesis and drug resistance of pancreatic ductal adenoca… DOI 10.1016/j.bbcan.2020.188423↗
- Harold Phillip Koeffler · 1 shared paper, 2022 · strength 0.16
- David W. Dawson · 1 shared paper, 2022 · strength 0.16
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.